|
|
|
|
|
Sponsored by: |
Stanford University |
Information provided by: | Stanford University |
ClinicalTrials.gov Identifier: | NCT00507624 |
Cancer immunotherapy has been shown to be effective in isolated instances, but ineffective in most patients. The reason for this inconsistency, and the conditions necessary for successful immunotherapy, are not well understood. Our studies in animal tumor models indicate that the effectiveness of IL-12-based immunotherapy depends upon the presence of a preexisting immune response to the tumor. The presence of T cell infiltrates and IFN-gamma expression in tumor indicate such an immune response. We therefore plan to evaluate the existing immune response in human tumor samples in an effort to identify those patients most likely to respond to therapy with IL-12.
Condition |
Cancer |
MedlinePlus related topics: | Cancer |
Study Type: | Observational |
Study Design: | Screening, Cross-Sectional, Defined Population, Prospective Study |
Official Title: | Evaluation of Pre-Exisiting Immunity Markers in Human Tumor Tissue Samples |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Robin M Cisco | 650-723-5570 | rcisco@stanford.edu |
United States, California | |||||
Stanford University Cancer Center | Recruiting | ||||
Stanford, California, United States, 94305 | |||||
Contact: Stanford Cancer Clinical Trials Office 650-498-7061 |
Stanford University |
Principal Investigator: | Jeffrey Norton | Stanford University |
Study ID Numbers: | VAR0018 |
First Received: | July 24, 2007 |
Last Updated: | July 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00507624 |
Health Authority: | United States: Institutional Review Board |